Overactive immune responses and lung cell damage exacerbate acute lung injury (ALI). Luteolin, a flavonoid commonly found in traditional herbs, shows potential as an anti-ALI agent in pharmacological and clinical research, although its biological mechanism is not fully understood. This study aims to investigate whether luteolin can ameliorate ALI through its immune-modulatory and antinecroptosis mechanisms. We found that luteolin significantly inhibits the cellular activity of the FLT3-dependent monocyte cell line MOLM-13 and BTK-dependent B-cell line TMD-8. Through molecular docking and HTRF detection, it was confirmed that luteolin inhibits BTK and FLT3 enzyme activity by binding to their kinase domains, with IC values of 0.78 and 0.35 μM, respectively. In a TNF-α-induced lung epithelial cell injury model, luteolin reduced the increased expression of , , and mRNAs by blocking the necroptosis signal TNF-α/BTK/MLKL. Furthermore, using a Balb/c mouse ALI model with intratracheal LPS infusion (5 mg/kg), it was observed that luteolin improved lung function and pathology, regulated immune cell infiltration, and reduced cell death in pulmonary tissues by inhibiting BTK and FLT3 protein phosphorylation. In conclusion, luteolin acts as a natural BTK and FLT3 inhibitor, effectively preventing ALI both and through its immune-modulating and antinecroptosis properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jafc.4c06704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Luteolin Mitigates Acute Lung Injury Through Immune Modulation and Antinecroptosis Effects by Targeting the BTK and FLT3 Signaling Pathways.
J Agric Food Chem
January 2025
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Overactive immune responses and lung cell damage exacerbate acute lung injury (ALI). Luteolin, a flavonoid commonly found in traditional herbs, shows potential as an anti-ALI agent in pharmacological and clinical research, although its biological mechanism is not fully understood. This study aims to investigate whether luteolin can ameliorate ALI through its immune-modulatory and antinecroptosis mechanisms.
View Article and Find Full Text PDFThe multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
Leuk Lymphoma
November 2024
Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Despite advancements in FLT3 inhibitors for treating acute myeloid leukemia (AML), drug resistance is common due to additional survival pathways and mutations.
- The novel multi-kinase inhibitor CG-806 shows promising results in effectively treating leukemia by targeting FLT3 and other kinases, outperforming current FLT3 inhibitors regardless of mutation status.
- CG-806's mechanism involves inducing cell cycle changes (G1 phase blockage in mutant cells and G2/M phase arrest in wild-type cells), with ongoing clinical trials to further explore its efficacy.
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Histopathology
June 2024
Department of Pathology, Yale New-Haven Hospital, Yale School of Medicine, New Haven, CT, USA.
Aims: Liquid biopsy (LBx)-based next-generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue-based NGS is infeasible.
Methods And Results: We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non-Hodgkin lymphoma (NHL), 43 plasma-cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B-cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML).
Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.
Bioorg Chem
May 2023
School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, China; Nantong Key Laboratory of Small Molecular Drug Innovation, School of Pharmacy, Nantong University, Nantong 226001, China. Electronic address:
A novel class of aminopyrimidine-based Bruton's tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) dual-target inhibitors based on the BTK inhibitor spebrutinib was designed for the treatment of acute myeloid leukemia. Representative compounds 14d, 14g, 14j and 14m effectively inhibited BTK, FLT3, and FLT3(D835Y) mutant activities with low nanomolar IC's. These compounds displayed potent antiproliferative activities against leukemia cells with IC's of 0.
View Article and Find Full Text PDFLuxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
PLoS One
March 2023
Moores Cancer Center, Division of Hematology, Department of Medicine, University of California, San Diego, San Diego, California, United States of America.
Luxeptinib (LUX) is a novel oral kinase inhibitor that inhibits FLT3 and also interferes with signaling from the BCR and cell surface TLRs, as well as activation of the NLRP3 inflammasome. Ongoing clinical trials are testing its activity in patients with lymphoma and AML. This study sought to refine understanding of how LUX modulates the earliest steps downstream of the BCR following its activation by anti-IgM in lymphoma cells in comparison to ibrutinib (IB).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!